Related Experiment Video
Updated: May 1, 2026
08:52
Performing Colonoscopic-Guided Pinch Biopsies in Mice and Evaluating Subsequent Tissue Changes
Published on: February 5, 2021
4.0K
Mucosal healing as a treatment for IBD?
Claudio Papi1, Annalisa Aratari
1Gastroenterology and Hepatology Unit, San Filippo Neri Hospital, Rome, Italy.
Expert Review of Gastroenterology & Hepatology
|March 25, 2014
Summary
Mucosal healing is a key goal for inflammatory bowel disease patients, potentially improving outcomes. However, standardized definitions and proven long-term benefits are needed for its use as a reliable endpoint.
Area of Science:
- Gastroenterology and immunology
- Inflammatory Bowel Disease (IBD) research
- Endoscopic evaluation techniques
Background:
- Mucosal healing is increasingly recognized as a critical therapeutic target in inflammatory bowel disease (IBD).
- Evidence suggests mucosal healing correlates with improved patient outcomes, including sustained remission and reduced hospitalizations/surgeries.
- Current challenges include the lack of a validated definition and inconsistent methodologies for assessing drug efficacy.
Discussion:
- Variability in study designs, definitions, and timing of endoscopic assessments hinders the comparison of treatment effects.
- The predictive value of mucosal healing for long-term clinical outcomes requires further robust evidence.
- Mucosal healing is currently considered a surrogate endpoint, with its definitive impact on disease trajectory still under investigation.
Key Insights:
- A standardized definition of mucosal healing is essential for consistent research and clinical application.
- Objective assessment of drug efficacy in IBD requires harmonized criteria for evaluating mucosal healing.
- Limited evidence currently supports mucosal healing as a strong predictor of sustained long-term clinical outcomes.
Outlook:
- Future research must focus on developing a standardized definition for mucosal healing in IBD.
- Prospective studies are necessary to definitively establish the impact of mucosal healing on long-term disease course.
- Establishing mucosal healing as a validated endpoint will refine IBD treatment strategies and improve patient prognoses.
More Related Videos
Related Concept Videos
01:21Inflammatory Bowel Disease V: Surgical Management
917
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
917
01:29Inflammatory Bowel Disease IV: Pharmacological Management
1.1K
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
1.1K
01:29Drugs for Treatment of Ulcerative Colitis in IBD
705
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
705
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
1.1K
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
1.1K
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
692
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
692
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
2.3K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
2.3K